Investment

down-icon
image
Invest in the world’s largest market with US Stocks

Features

down-icon
support-icon
Pro Tools for Pro Traders
Uncover the powerful trading features

Pro Features

icon
support-icon
Built for Investors
Experience investing with simplified features

Pockets

icon

Fees

Safety

Academy

down-icon

More

down-icon
support-icon
Support

About Us

arrow-icon

Pluang+

|

assetIcon

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.


Technical Indicators

|

|

|

Overall Summary

Bearish (0)

Neutral (10)

Bullish (17)


Performance

ALNY ROI

arrow
+55.27%

% from 52W High

-2.75%
$279.13

52W Low: $143.31

26 Apr 2024

52W High: $287.01

29 Aug 2024


News

Pluang News
Pluang News

Benzinga

2mo

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Alnylam ... - Benzinga



People Also Bought

Pluang
Pluang
SE
Sea Limited
+4.21%

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions



Let’s trade or invest in this asset by signing up or logging in!

register_card

Let’s trade or invest in this asset by signing up or logging in!

You can also download our app!

item